NIA 2015/16 delivered in partnership with:

NHS Innovation Accelerator

Summit

6 July 2016

Create the conversation @NHSAccelerator

Foreword Welcome to the NHS Innovation Accelerator Summit 2016.

Exactly one year ago today we announced 17 Fellows and their compelling

evidence-based innovations. Since then, the NHS Innovation Accelerator

(NIA) has supported the Fellows to scale their innovations across the NHS in

order to improve patient outcomes and reduce cost.

The NIA aims to deliver on the commitments detailed within the Five Year

Forward View - giving people more equitable access to high impact

innovations by focusing on the conditions and cultural change needed to

spread innovations that matter to patients at pace and scale.

I am delighted today to have the opportunity to congratulate the Fellows on

their progress and to celebrate those NHS organisations who have adopted

new ways of working.

I also want to thank all those who have helped make the NIA so successful

during its first year – including the NIA Mentors, colleagues at NHS England,

the Academic Health Science Networks, the Health Foundation, and the many

other individuals and organisations who have supported the programme.

Through this collective endeavour, we have achieved:

345 additional NHS providers and commissioners using NIA innovations

12 awards won

£8.9 million external funding secured

The progress we have seen in accelerating innovations over the last 12

months is something the NHS should be really proud of.

Professor Sir Bruce Keogh

Medical Director, NHS England

NHS Innovation Accelerator Fellows

Andrea Haworth: SAPIENTIA™ “We’ll be working alongside Congenica to deliver the vision that NHS England and Genomics England have of using genomic testing to unlock the potential of genetic medicine to benefit our patients and transform the NHS.” [Professor Graeme Black,

Professor of Genetics and Ophthalmology at Central Manchester University Hospitals Foundation Trust]

SAPIENTIA™ is a genome analytics software enabling

healthcare professionals to interrogate the human

genome for pathogenic mutations likely to be the cause of a patient’s

inherited disease. This technology, developed from the Deciphering

Developmental Disorders translational research study, is particularly relevant

for rare diseases. On average it takes over five years for patients to receive a

diagnosis; by utilising genome and clinical data, SAPIENTIA™ facilitates the

identification and interpretation of disease causing variants resulting in a

speedier diagnosis and better clinical decision support for patients with rare

genetic disease.

During the NIA, Andrea has included a focus on:

Proactively supporting laboratories in their implementation of

SAPIENTIA™ through training, events and the creation of an

implementation toolkit

Sharing of scarce expertise particularly around bioinformatics

Demonstrating high levels of regulatory compliance

Developing a new website to market SAPIENTIA™

SAPIENTIA™ is now being used in 10 NHS labs across England – nine of these

whilst on the NIA. Andrea is also working with UCB Pharma Company and the

New York Genome Centre. This year SAPIENTIA™ secured an Innovate UK

grant for Multi-omic solutions for rare diseases and was awarded a Health

Enterprise East Award.

Anna Moore: i-Thrive ‘’There is now a welcome recognition of the need to

make dramatic improvements in mental health

services. Nowhere is that more necessary than in

support for children, young people and their families.

Need is rising and investment and services haven’t

kept up.’’ [Simon Stevens Future Minds March 2015]

i-Thrive is transforming the way mental health

services are organised for children and adolescents.

The model incorporates a new way of delivering

support services alongside ‘shared decision making’ – so that children and

young people have much greater control over their care, which is integrated

along the pathway from prevention through to complex treatment. i-Thrive

has been shown to reduce waiting times and improve the experience of care

– by accurately assessing young people the first time they ask for help, and

delivering the care that they need more quickly.

During the NIA, Anna has included a focus on:

Aligning the i-Thrive model with the requirement for all CCGs to develop

Transformation Plans for mental health services

Recruiting “accelerator sites” to form an i-thrive Community of Practice,

where sites work together to adapt and implement i-thrive within local

contexts

Setting up an i-Thrive academy to build capacity for new ways of working

Securing significant funding to support scaling of the model

Anna is now working with 40 NHS organisations and has developed a

community of practice covering approximately 20% of England's young

people. She has established an i-Thrive academy in London, which provides

training for clinicians in shared decision making and developed an i-Thrive

‘implementation’ toolkit. Anna has successfully secured more than £1m to

support the spread of i-Thrive.

Anne Bruinvels: OWise “When I received the diagnosis of breast cancer my world

was turned upside down. In addition to treatment plans,

examinations and results there was so much anguish and

sadness. OWise creates order in this chaos and keeps it

that way. It is truly a fantastic support!” [Patient]

OWise is the first mobile app and website to offer people

with breast cancer personalised medical information

throughout their treatment. Designed by Anne, OWise

allows people to record in real time their experiences, including side effects

and overall quality of life, and collates for research purposes fully

anonymised patient-reported data with a view to improving clinical outcomes

for cancer.

During the NIA, Anne has included a focus on:

Building relationships and networks with UK-based clinicians, charity and

patient organisations to adapt and refine OWise

Preparing OWise and marketing materials for its UK launch

Working with charities to support the dissemination of OWise

Securing funding for the ongoing scaling of OWise

The English version of OWise breast cancer was launched in the UK in February 2016. It is already being recommended by a number of clinical centres, and 400 people have downloaded the UK version of the app. Anne has been working with Macmillan Cancer Support who are promoting OWise to its supporter base.

Since joining the NIA, OWise has received a coveted European eHealth grant, which enabled the organisation to further strengthen its team and expand its reach. OWise recently had a peer-reviewed paper published in the Journal of Medical Internet Research – Cancer, endorsing the use of OWise as a shared decision making tool.

Ben Underwood: Brush DJ “I use it for my kids. They are brushing longer

instead of trying to be the first one finished.”

[Parent]

Brush DJ is the only evidence-based, free, NHS

approved app that motivates an effective self-

care oral hygiene routine by playing two

minutes of the user’s music - making tooth-

brushing fun. Ensuring children adopt good

oral hygiene from a young age will help prevent a number of dental diseases

for a lifetime.

During the NIA, Ben has included a focus on:

Improving access and the user experience by refining the Brush DJ app

for android and Apple products and including free music, links to

streamed music and translation in to 13 different languages

Raising awareness of the Brush DJ through a variety of media

opportunities and engaging NHS England and Public Health England to

promote Brush DJ via existing health channels

Publishing a peer reviewed user perception study of the Brush DJ app in

the British Dental Journal

To date, Brush DJ has achieved nearly 250,000 downloads in 193 countries

and almost 140,000 views of the educational videos within the app. A new

version released on android in April 2016 is receiving 90% 5* ratings on

Google Play. Brush DJ has amassed a following on social media and been

featured in national press - from the Daily Mirror to the Telegraph. Great

Ormond Street Hospital is now promoting Brush DJ, alongside a number of

other hospitals, Local Authorities and dental practices.

Bernadette Porter: NeuroResponse

“This is a great service, so well designed, I wish we had it last month might have stopped me going to hospital.” [Patient]

NeuroResponse is a service model that gives

people with Multiple Sclerosis more control over

their care. It includes a telephone triage/advice

line staffed by specialist nurses, email advice

services for GPs, and a video clinic linking a

specialist’s neurology team with the patient and

local clinical team. Using the telephone triage service, patients and staff can

discuss physical, mental and social care needs, agree care plans and share

information.

During the NIA, Bernadette has included a focus on:

Building the clinical and economic evidence base for NeuroResponse

Developing an emergency response service and unique testing kit for

patients with suspected urinary tract infections - avoiding the need for a

hospital visit and giving people more control over their care

Offering 24/7 telephone triage and assessment services as the first

specialist neurology hub for NHS 111 in collaboration with all London

CCGs and the UK MS Society

Engaging with Yorkshire and Humber AHSN to determine how to test and

refine NeuroResponse in a rural area

Creating governance frameworks for data sharing and workforce

Bernadette now has evidence to show a 22% health improvement (using the

EQ5D5L measure) for those using NeuroResponse with savings of £2,500 per

patient per relapse compared to standard NHS care. More recently,

Bernadette has begun working with NIA innovation, Patients Know Best as a

platform for NeuroResponse. She has also secured £420,000 to support

wider adoption.

Dharmesh Kapoor: EPISCISSORS-60

“I would not want to deliver in a London hospital that does not use the EPISCISSORS-60.” [Patient]

Approximately 15% of all births require an episiotomy. Obstetric anal sphincter injuries (OASIS) relating to episiotomy affect 30,000 women each year with approximately 12,000 women suffering bowel incontinence. The Episcissors-60 is designed to ensure a 60-degree angle during episiotomy in

accordance with the Royal College of Obstetrics recommendations, thereby reducing the risk of injuries. The cost to the NHS of OASIS is approximately £57 million annually including repair (£1,625 per patient), elective caesarean sections and litigation costs. OASIS can have a devastating impact on the quality of a new mother’s life.

During the NIA, Dharmesh has included a focus on:

Building the evidence base for the Episcissor-60 by working with Croydon

University Hospital

Raising awareness of OASIS (and Episcissors-60) through scientific

learning events and exhibitions

Providing free samples to maternity unites for trial and evaluation

Working with NHS England to secure a Best Practice Tariff or similar

innovation tariff for a 60-degree episiotomy

Partnering with the Department of Health so that Episcissor-60 are now

available at a discount to the NHS on the NHS Supply Chain with DH

receiving royalties in international sales

Since being on the NIA, the EPISCISSORS-60 has been adopted by 10 English hospitals with excellent feedback from Trusts involved. Results have shown a reduction in OASIS in instrumental births down from 8.8% to 0.6% and in normal births down from 4.3% to 0%.

Francis White: AliveCor’s Kardia™ “I love my AliveCor and can’t praise it highly enough, it’s so quick and easy to use and always close to hand. Since having my AliveCor I feel in control and very reassured” [Diane Fairclough, Patient]

AliveCor’s Kardia™ Mobile is the world’s first mobile ECG that instantly analyses and interprets heart recordings. The device identifies paroxysmal atrial fibrillation (AF), a leading cause of stroke. Kardia™

Mobile can be embedded in the case of any smart phone (Apple or Android), allowing users to capture a heart recording anywhere, anytime. Results are analysed immediately, and can be shared with a doctor for instant diagnosis.

During the NIA, Francis has included a focus on:

Raising awareness of Kardia™ amongst GPs, CCGs and the public directly

and via clinical and patient-charity advocates

Working with primary care sites where there is readiness to redesign and

test an ‘earlier intervention’ AF care pathway

Securing media coverage to raise awareness of the AliveCor Kardia™

Easing access by making available Kardia™ via NHS supply chain

Building the case for the device through evaluation of the economic

benefits of using Kardia™

Since being part of the NIA, AliveCor’s Kardia™ has recorded 1.3m ECGs in Great Britain and at least 33 NHS organisations are now using the device. West Coast CCG are now creating a Local Commissioned Service (LCS) for the AliveCor Kardia™ in primary care for the diagnosis of Palpitations. Kardia™ was accepted as one of 11 innovations being tested within the Care City Test Bed in North East London – which will evaluate the device’s impact within a population of over a million people. AliveCor has received extensive media coverage including being featured on Sky News and in both the Financial Times and Guardian. It was also named by the Kings Fund as one of eight technologies that will change health and care.

Lloyd Humphries: Patients Know Best

“Very few doctors properly understand my condition

so going to an unfamiliar medical team can be

terrifying. With Patients Know Best, it’s very

reassuring that I can reach my entire medical team

anywhere in the world – this makes me feel far more

independent.” [Patient]

Patients Know Best (PKB) enables patients to hold all

their medical information in a single record owned by them. This single

record puts the patient at the centre of their care, empowering their health

network and challenging traditional models of care. With patients able to

invite anyone they wish to see their profile, they can construct a strong and

comprehensive care network best suited to them, made up of diverse clinical

teams, friends and family able to support out of hospital care.

During the NIA, Lloyd has included a focus on:

Creating a compelling case for the adoption of PKB across a range of

sites: hospitals, CCGs, social care, specialist centres and health economies

Contributing to national discussions on the role of Personal Health

Records with NHS England, NHS Digital and Public Health England

including how to share consent across organisation boundaries

Building partnerships with organisations who share PKB’s vision and bring

complementary skills to the challenge of scaling including charities, other

NIA innovations, and private companies

Securing funding to support the continued scaling of PKB

Since joining the NIA, PKB has developed 52 new services, equating to a 58%

growth in the number of sites using the platform. More than 217,000

additional patient records have been created. PKB has also won a series of

impressive awards including: EU eHealth Champion 2015 and the 2016

Healthcare Tech and You Award.

Maryanne Mariyaselvam: Non-Injectable Arterial Connector

28% of health care staff said they had seen

adverse events in their routine clinical practice.

98% of health care staff believed it was

important to have a device that prevents wrong

route drug administration and prevents arterial

line infections. [Survey of >250 NHS staff using

the NIC]

The Non-Injectable Arterial Connector (NIC)

enables conventional arterial line sampling for all

patients in operating theatres and intensive care and it also improves safety

by preventing wrong route drug administration. If medication is accidentally

given to a patient via the wrong route, there is risk of damage to a patient’s

blood vessel and surrounding tissue and in extreme circumstances surgical

amputation.

During the NIA, Maryanne has focused on raising awareness of and

accountability for wrong route drug administration including:

Engaging with individual hospitals through infection control teams and

practice development nurses

Publishing papers and presenting at major ‘safety’ conferences

Engaging national leaders as advocates for patient safety

Collecting evidence to develop a compelling case for wrong route drug

administration to be included on the Never Events list

Since becoming an NIA Fellow, Maryanne has more than doubled the number

of Trusts using the NIC. She is exploring opportunities to make the purchase

of NIC easier and cheaper via NHS procurement routes. Through the NIA,

Maryanne has also been supported by the AHSNs who are helping to boost

the adoption of the NIC in their localities.

Matt Jameson-Evans: HealthUnlocked

“Coming together with others who are going

through cancer is transforming my experience… I

have been able to compare notes, information,

frustration and even anger at times with [people]

who understand.” [Patient]

HealthUnlocked is one of the world’s largest social

support networks for health. It connects patients,

caregivers and health advocates safely online with guidance from leading

credible health organisations. People share their experiences of conditions,

symptoms, treatments, and health services. These are catalogued in an

intelligent database which signposts relevant content to people based on

their profile.

During the NIA, Matt has focused on understanding the value and application

of HealthUnlocked within the NHS:

Partnering with Macmillan Cancer Support to develop personalised

electronic care plans

Developing a new personalisation engine product for CCGs and place-

bases care sites which navigates people to local services based on need

Measuring impact through a study by King’s Health Economics using the

Patient Activation Measure (licensed by Insignia Health)

Since joining the NIA, HealthUnlocked website traffic has increased to nearly

4 million views per month. HealthUnlocked is now the third most visited

health site in the UK. Matt has established a partnership with Macmillan

Cancer Support which will offer every person newly diagnosed with cancer a

personalised care plan through HealthUnlocked. Since April 2016 Matt and

his team have signed 14 new contracts including one with Torbay CCG.

Neil Guha: Scarred Liver Pathway “Taking part in this project changed my life. It

enabled me to take to control of my life once

again after a period of alcohol dependency. The

whole process has had a positive effect on myself

and my family. Find it hard to say how lucky I feel

to have taken part in the project. A real game

changer for me!” [Patient]

Liver disease is now the fifth largest killer in the

UK. Currently 50% of new diagnoses of liver

cirrhosis occur only after emergency admission to hospital.

Neil has co-developed a diagnostic pathway to detect asymptomatic chronic

liver disease at the critical stage where it can either progress or reverse. The

pathway combines both the identification of people at risk of chronic liver

diseases and the use of proven diagnostic tests to detect and stratify the risk.

It aims to provide a seamless pathway between primary and secondary care.

During the NIA, Neil has focused on:

Refining the pathway based on implementation, feedback and outcomes

within two different populations - Nottingham and Leicester

Developing the economic case for the new pathway with the University

of Nottingham, led by Professor Rachel Elliot

Negotiating with commissioners to incorporate elements of the pathway

Collaborating with implementation scientists at East Midlands AHSN to

produce a research report on how CCGs interact with innovation

Engaging with critical stakeholders to raise the profile of liver disease

Thus far, the pathway has been tested with 25,000 patients, and has been

shown to increase the detection of significant liver disease, and to be cost-

effective. Patient feedback is excellent. Neil has secured funding from East

Midlands AHSN to continue scaling the Scarred Liver Pathway during 2016.

Paul Volkaerts: Nervecentre

“The deployment of Nervecentre software means

that we can reduce the burden of paperwork for

nurses and clinicians, releasing more time to

spend with patients. The use of mobile

technology also allows doctors and nurses to

have all the tools and information at hand to be

able to respond rapidly and effectively to

deteriorating patients.” [Heather McClelland,

Calderdale & Huddersfield NHS Trust]

Paul founded Nervecentre software in 2010 to address a gap in the market of

strong clinical collaboration tools. His aim was to improve hospital

communication in order to reduce delays in patient care and inefficiencies.

Nervecentre software provides a whole hospital platform that delivers

electronic observations, handover, task management and clinical

assessments; and allows governance and escalation management to be

added to any hospital process.

During the NIA, Paul has focused on creating a compelling case for mobile

technology - as a platform for safer, more efficient health care by:

Applying Nervecentre to critical NHS challenges in both patient safety

(e.g. Sepsis) and operational efficiency (e.g. the emergency department)

Building the evidence base for Nervecentre

Raising the profile through a range of mechanisms including winning a

number of patient safety awards

Whilst on the NIA, eight additional NHS organisations have adopted

Nervecentre and more than 20,000 nurses and doctors now use Nervecentre

daily in the NHS. Evaluation has shown that Nervecentre reduces unplanned

admissions (£1m savings per year), improves nurse efficiency and allows

doctors to spend more time with their patients (from 2.9% to 7.3%).

Nervecentre was also named 14th fastest growing technology company in

the UK by Deloitte.

Penny Newman: Health Coaching

“Health Coaching has enabled myself and my son

to find ways of managing his relentless treatment

regime, without the negative baggage which

comes with ‘telling,’ someone what to do. Health

Coaching isn’t a luxury or an extravagance. It’s

the only option for positive, humane health and

care relationships.” [Mother]

With Health Education East of England, Penny has co-designed and led health

coaching training for clinicians. Trained clinicians can enable people to gain

the knowledge, skills and confidence necessary to become more active

participants in their care, reach self-identified goals and adopt healthier

behaviours. Health coaching is a person-centred process and widely

applicable to all long-term conditions, covering prevention, decision making,

self-management and medication adherence.

During the NIA, Penny has focused on building a social movement of

clinicians and staff across the NHS, working together to:

Co-design compelling materials to reframe the vision and narrative with

support from a wide range of experts

Develop an implementation toolkit in collaboration of 18 organisations

Create of an online community to support practitioners

Penny secured resources to roll out health coaching across the East of

England and nationally. At least 3,200 clinicians are now trained or booked to

receive health coaching training, including 60 additional health coaching

trainers. The number trained has quadrupled in 2015/16 from 2014/15.

A national launch of the new health coaching tools will take place later this

year with the support for the Innovation Agency (formerly, North West Coast

AHSN), Yorkshire and Humber AHSN, Eastern AHSN and Health Education

East of England.

Peter Hames: Sleepio

“I’ve had quite bad sleeping problems for a number of years, and not much I have tried in the past has helped…the Sleepio course has really helped me out – I can’t recommend it highly enough. [It’s] a very well thought out and structured, practical programme which has helped me deal with something that has plagued my life for years – which has been pretty tough at times.” [Mr Richardson, Patient]

Sleepio is a digital sleep improvement programme (available via web and mobile), clinically proven to help

overcome even long-term poor sleep. Over a number of weekly sessions, users are taught proven cognitive and behavioural techniques by a virtual sleep expert to help them get their schedule, thoughts and lifestyle on track.

During the NIA, Peter has tested multiple routes to increase access including:

Direct marketing to the public: Sleepio has featured in multiple media

outlets, and is available for purchase via Boots.com

Sleepio is offered as an alternative to traditional therapies via Improving

Access to Psychological Therapies (IAPT)

Peter has engaged with CCGs and Community Pharmacists about

potential opportunities to offer Sleepio as an alternative to sleeping pills

As part of a new pilot, Sleepio will be offered to NHS employees in

2016/17

One Local Authority is exploring the potential to include Sleepio within

their population suicide prevention programme

Sleepio is now available to patients accessing several IAPT services in the

North West of England. Routine data shows that Sleepio is exceeding national

targets for recovery – 68% of anxiety and depression patients using Sleepio

move to recovery, versus a national average across IAPT interventions of

45%. Multiple global employers are now offering Sleepio as a benefit, and the

team has published evidence that it improves both sleep and productivity.

Peter Young: PneuX Prevention System

“We are hugely impressed with the direct benefits

to patient safety, through avoidable harm and

improving outcomes. We urge health care

providers … to ensure the system is adopted as best

practice. From a patient’s perspective, this is an

opportunity that cannot be ignored” [T Fernandes,

Co Chair East of England Citizen’s Senate]

The PneuX is designed to stop ventilator-

associated pneumonia (VAP), the leading cause of

hospital-acquired mortality in Intensive Care Units affecting up to 20,000

patients each year, with a 30% mortality rate costing the NHS £10k - £20k per

episode.

PneuX is a cuffed ventilation tube and an electronic cuff monitoring and

inflation device which prevents leakage of bacterial laden oral and stomach

contents to the lung – a problem associated with all standard tubes.

During the NIA, Peter has included a focus on:

Engaging a growing community of clinical champions through national

leaders and presentations at key conferences

Building the economic case: an independent health economic evaluation

at New Cross hospital in Birmingham demonstrated a saving of £718 per

patient who received treatment with the PneuX

Developing financial incentives for avoidance of leakage of bacteria to

the lungs, including through the Commissioning for Quality and

Innovation (CQUIN) framework.

Peter has had international interest in PneuX and is currently working with

Massachusetts General Hospital to implement the device. Additionally, he

has worked with the specialised commissioning team at NHS England

(London region) to secure a local CQUIN to incentivise uptake of the Pneux

Piers Kotting: Join Dementia Research

“One of the reasons I wanted to get involved in the research was the fact that it was quite debilitating, frightening when Ron was diagnosed with Alzheimer’s and if I can help in anyway, it might not help us but it might help the next generation. And as ex-teachers, we would like to help the future.” [Mr and Mrs S]

Dementia affects about 850,000 people in the UK, with a cost of £26 billion per annum. 60,000 deaths a year are directly attributable to dementia. The

only way to beat the condition is through research.

Join Dementia Research (JDR) allows people to easily register their interest of participating in research via an online form and matches them to appropriate studies. Once matched, individuals and researchers are able to discuss participation in studies.

During the NIA, Piers has included a focus on:

Raising public awareness via a range of channels including national media

and NHS Choices

Expanding the community of patient, clinical and academic advocates

Enrolling people through NHS services including memory clinics and GP

practices

Developing an implementation plan with NHS England’s dementia

programme team to achieve the Prime Minister’s challenge of dementia

2020

Achieving interoperability with electronic health records

Since joining the NIA, there are now 19,138 people signed up, up from 7,282

a year ago – a 163% increase. The number of people enrolled in studies

through JDR is now 5,364, up from 1,346, a 299% increase. 132 NHS Trusts

have ordered promotional materials compared to 56 before the NIA.

Simon Bourne: myCOPD

“Last year, before using myCOPD I had 12 exacerbations, this year I have had just two. I now know when and how to take my medication, when to use my rescue pack and perform my rehab exercises most days” [Patient]

Chronic Obstructive Pulmonary Disorder (COPD) is the second most common cause of hospital admissions in the country costing the NHS over £800m in direct healthcare costs. Studies show that 90% of people with COPD are unable to take their medication correctly.

myCOPD is an integrated online education, self-management, symptom reporting and pulmonary

rehabilitation (PR) system to help people with COPD manage their condition more effectively. The platform has shown to correct 98% of inhaler errors without any other clinical intervention. Healthcare professionals are provided with a dashboard to allow them to plan, monitor and manage patients remotely.

During the NIA, Simon has included a focus on:

Refining myCOPD, along with a multi-morbidity platform to include

diabetes and asthma.

Building the evidence base through a large randomised control trial and

health economic case

Developing website and marketing materials, contacting 100s of people

in over 100 Clinical Commissioning Groups and attending key conferences

Building national and international partnerships to support distribution

Three CCGs have now implemented MyCOPD covering a population of

32,000. Simon has demonstrated that the PR feature of MyCOPD is cheaper

and delivers better patient outcomes than traditional face-to-face PR classes.

MyCOPD has demonstrated a reduction in acute admissions for severe

patients saving the average CCG £370,000 per year.

Award Categories

Prizes to be awarded at the Summit

Best Progress Presented by: Professor Sir Bruce Keogh This award is for the Fellow who has made the best all round progress in scaling their innovation - measured in terms of uptake, population impact, evidence base and engagement of influential champions. The winner of this award will have gathered the evidence to show the impact of their innovation on parameters important to the system - improved health outcomes and reduced cost. The award takes into account the barriers the Fellow has had to overcome to ensure wider uptake across the NHS. The NIA Programme Board selected a Fellow for this prize on 28th June 2016.

Best Participant Presented by: Dr Jo Bibby, The Health Foundation The winner of this award is the Fellow who has most fully participated in the NIA during their first year. She / he attended all quarterly events, submitted action plans, 12-week sprint plans, baseline and progress reports on time. The winner of this award has also attended additional ad-hoc sessions and generally used the full range of support available through the NIA. In addition, this Fellow is an active champion for the NIA. This award was chosen by the NIA Core Team based on records of the Fellows and their interactions with elements of the NIA.

Best Pitch Presented by: Dr Liz Mear, Innovation Agency (North West Coast) The winner of this award delivered a succinct, articulate and compelling presentation at the Summit. She/ he spoke confidently providing both the overview of his/ her innovation and progress, as well as providing insights and reflections. Where slides or visuals were used, the Fellow was at ease with the transitions between slides and the content/ artifacts presented complemented the spoken word. The winner of this award kept within the allocated time frame of three minutes. He/she made an impact on the audience. Each Fellow will be giving a presentation on their innovation and progress made during the Summit. The audience will be asked to vote at the end of the presentations as to which of Fellow made the best pitch via Sli.do.

Best NIA Peer Presented by: Professor Sir David Fish, UCLPartners This award goes to the Fellow who has provided exemplary support to his/ her NIA colleagues during the first year of the NIA. The Best Peer actively shared learnings, insights, useful documents and contacts. He/she contributed to group discussions – on and offline - and was actively available to be contacted by Fellows to explore opportunities and/or provide feedback when needed. The NIA Fellows nominated a peer for this award through an anonymous process.

NHS Innovation Accelerator 2016

On 17 June 2016, a second call for applications to the NIA was announced for evidence-based innovations ready to scale that will improve health outcomes and reduce cost. This year we are looking to recruit an additional 8 Fellows to join the existing cohort with innovations that tackle one or more of the following challenges:

Prevention

Earlier intervention

Long term condition management Applications close on 1 August 2016 with new Fellows to be announced at the end of October 2016. For more information on the NIA 2016, please visit www.england.nhs.uk/ourwork/innovation/nia/ Or contact us: NIA@uclpartners.com or @NHSAccelerator NIA 2016/17 delivered in partnership with: